中国经济网北京8月4日讯 君实生物(688180.SH)今日股价下跌，截至收盘报37.66元，跌幅1.10%。该股 目前处于破发状态。 君实生物于2020年7月15日在上交所科创板上市，发行数量为8713万股，发行价格为55.50元/股，保荐 机构、主承销商为中国国际金融股份有限公司，联席主承销商为国泰君安证券股份有限公司、海通证券 股份有限公司(2家公司现已合并为国泰海通证券股份有限公司)。 上市首日，君实生物股价最高报220.40元，此后该股一路震荡下滑。该股目前处于破发状态。 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元， 较原计划多17.97亿元。君实生物于2020年7月8日发布的招股说明书显示，该公司计划募集资金27.00亿 元，分别用于创新药研发项目、君实生物科技产业化临港项目、偿还银行贷款及补充流动资金。 君实生物首次公开发行股票募的发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。 君实生物2022年度向特定对象发行A股股票募集资金情况为，根据中国证监会出具的《关于同意上海君 实生物医药科技股份有限公司向特定对象发行股票注册的批复》 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and listed on July 15, 2020. The company specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [7]. - The main revenue sources include 84.18% from drug sales, 12.08% from technology licensing, and 3.73% from other sources [7]. Product Development - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi's Tifcemalimab is the first anti-tumor BTLA monoclonal antibody to enter clinical development, with ongoing Phase III trials and several combination studies with Toripalimab [2]. Recent Collaborations - On October 27, 2023, Junshi announced collaborations with several institutions, including Peking University and the Chinese Academy of Sciences, to develop a monkeypox recombinant protein vaccine [3]. Financial Performance - For the first quarter of 2025, Junshi reported revenue of 5.01 billion yuan, a year-on-year increase of 31.46%, while the net profit attributable to shareholders was -235 million yuan, reflecting a 17.01% year-on-year growth [8]. Market Position - As of March 31, 2025, Junshi had 29,400 shareholders, with an average of 25,987 circulating shares per person, indicating a slight decrease in share distribution [8]. - The company operates within the pharmaceutical and biotechnology sector, focusing on innovative drugs and biopharmaceuticals [8].

Group 1 - The stock prices of several biotech companies have experienced declines, with 康方生物 (09926.HK) down 5.37%, 泰格医药 (03347.HK) down 3.34%, 药明康德 (02359.HK) down 3.15%, and 君实生物 (01877.HK) down 2.64% [1]

Group 1 - The core viewpoint of the article highlights that Junshi Biosciences has seen a net financing inflow of 34.75 million yuan in the last week, ranking 274th in the market [1] - The company had a total financing purchase amount of 385 million yuan and repayment amount of 350 million yuan during the same period [1] - Junshi Biosciences operates in various sectors including biopharmaceuticals, Shanghai market, FTSE Russell, MSCI China, and innovative drugs [1] Group 2 - Over the past five days, the main capital outflow from Junshi Biosciences was 63.86 million yuan, with a decline of 1.76% in the same period [1] - In the last ten days, the total main capital outflow reached 172 million yuan, resulting in a decline of 2.66% [1] - Junshi Biosciences was established in 2012 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of approximately 985.69 million yuan [1]

Group 1 - The core viewpoint of the article highlights the financial performance and market activity of Junshi Biosciences, indicating a recent decline in stock price and significant capital outflow [1][3] - As of August 1, 2025, Junshi Biosciences' stock closed at 38.08 yuan, down 0.99%, with a trading volume of 15.26 million shares and a transaction amount of 589 million yuan [1] - The latest quarterly report shows total revenue of 501 million yuan, a year-on-year increase of 31.46%, and a net profit attributable to shareholders of 234.88 million yuan, up 17.01% [1] Group 2 - The company has a current liquidity ratio of 1.398 and a quick ratio of 1.204, indicating a stable financial position [1] - Junshi Biosciences has invested in 41 companies and participated in 39 bidding projects, showcasing its active engagement in the industry [2] - The company holds 151 trademark registrations and 116 patents, along with 133 administrative licenses, reflecting its strong intellectual property portfolio [2]

爆款、上市、融资、出海，这是今年中国创新药产业的四大关键词。这些动作绝非一朝一夕的博弈，而 是历经过去数年的资本"寒潮"、行业波动和周期冷暖后，自我倒逼、奋力突围、穿越周期的结果。 把镜头拉回上海。去年上海三大先导产业规模达1.8万亿元，其中生物医药产业规模超9800亿元。今 年，这一数字有望突破万亿大关。行业迎来拐点，企业何尝不是。"上海药圈新拐点"系列报道，将独家 专访三家扎根上海的上市药企掌舵人，共同讲述当全球创新药行业进入"中国时间"，作为上海打造生物 医药产业高地的侧影，他们如何腾挪和突破，迎接属于自己的新拐点。 节目第三集，将走进老牌科创板上市药企——君实生物。它是第一个国产PD-1药物的拥有者，也是第 一批带着国产创新药出海的中国公司之一。它曾在三年内，实现了两款抗新冠新药的商业化，目前总市 值约400亿元。在新任总经理邹建军的掌舵之下，这家扎根上海13年的创新药企，今年能否迎来新的发 展拐点，第一财经记者将与之深度对话。 ...

8月1日，君实生物跌0.99%，截至发稿，报38.08元/股，成交5.89亿元，换手率1.99%，总市值390.96亿 元。君实生物股价已经连续3天下跌，区间累计跌幅7.12%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售84.18%，技术许可及特许权使用收入12.08%，其他(补 充)3.73%。 从基金十大重仓股角度 来源：新浪基金∞工作室 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 基金名称基金代码基金经理持股数量(股)占流通股比例(%)占基金净值比(%)持股数量变动(股)嘉实上证 科创板生物医药ETF588700王紫菡2498300.03264.15-242422 ...

Group 1 - The stock price of Junshi Biosciences-U closed at 38.46 yuan on July 31, down 1.69% from the previous trading day [1] - The trading volume on that day reached 782 million yuan, with a turnover rate of 2.60% [1] - Junshi Biosciences-U is focused on the research, production, and commercialization of innovative drugs, with key products including Toripalimab, targeting oncology and autoimmune diseases [1] Group 2 - In 2025, the National Medical Products Administration has approved over 20 Class 1 innovative drugs for market launch, setting a record for the past five years [1] - There have been more than 50 licensing cooperation events for domestic innovative drugs going abroad, with a total disclosed cooperation amount exceeding 48.4 billion USD [1] - On July 31, the net outflow of main funds for Junshi Biosciences-U was 49.655 million yuan, accounting for 0.17% of the circulating market value [1]

7月31日，上证指数跌1.18%，收报3573.21点，恒生指数跌1.6%，收报24773.33点。 君实生物-UAH溢价达64.6%，位居AH股溢价率第59位。当日收盘，君实生物-UA股报38.46元，跌幅 1.69%，H股报25.5港元，下跌4.14%。 资料显示，上海君实生物医药科技股份有限公司成立于2012年12月,是一家以创新为驱动,致力于创新疗 法的发现、开发和商业化的生物制药公司。凭借卓越的创新药物发现能力、先进的生物技术研发、全产 业链大规模生产技术和极具市场潜力的在研药品组合,君实生物在肿瘤免疫疗法,以及自身免疫系统疾 病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面极富潜力。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Group 1: Company Overview - Junshi Biosciences was founded on December 27, 2012, and listed on July 15, 2020, with its main business involving the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's revenue composition includes 84.18% from drug sales, 12.08% from technology licensing, and 3.73% from other sources [7]. Group 2: Product Development and Pipeline - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries [2]. - Junshi's Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III trials and several combination studies [2]. Group 3: Recent Collaborations and Innovations - On October 27, 2023, Junshi announced collaborations with several institutions to develop a monkeypox recombinant protein vaccine, currently in preclinical development [3]. - The company is also working on other vaccine candidates, including Zika virus vaccines, through partnerships with research institutions and universities [3]. Group 4: Financial Performance - For the first quarter of 2025, Junshi reported revenue of 5.01 billion, a year-on-year increase of 31.46%, while the net profit attributable to shareholders was -2.35 billion, reflecting a 17.01% year-on-year increase [8].